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Recent research on the chemistry of natural products from the author’s group that led to the receipt of the
ACS Ernest Guenther Award in the Chemistry of Natural Products is reviewed. REDOR NMR and synthetic
studies established the T-taxol conformation as the bioactive tubulin-binding conformation, and these results
were conﬁrmed by the synthesis of compounds which clearly owed their activity or lack of activity to whether
or not they could adopt the T-taxol conformation. Similar studies with the epothilones suggest that the current
tubulin-binding model needs to be modiﬁed. Examples of natural products discovery and biodiversity
conservation in Suriname and Madagascar are also presented, and it is concluded that natural products chemistry
will continue to make signiﬁcant contributions to drug discovery.
My ﬁrst real exposure to natural products chemistry came in
my third and ﬁnal year as an undergraduate at Cambridge
University, when I attended a course of lectures on the chemistry
of natural products by the Nobel Prize-winning chemist Sir
Alexander Todd (later to become Lord Todd). The lectures
included many references to his own work in the ﬁeld, with
stories of his early work on the structure of cholesterol, the
structure and function of various vitamins, and the structures
of the nucleotides and nucleosides, and I was fascinated by the
complex structures and biological importance of these sub-
stances. It was during this course that I decided to study the
chemistry of natural products, and this study has been one of
the loves of my life for the last 48 years.
Within the large ﬁeld of natural products chemistry, I was
particularly drawn to those compounds with biological activity,
especially anticancer activity, and much of my research has been
centered around the study of naturally occurring anticancer agents.
I was fortunate to be funded by NIH for work in this area soon
after my move to Virginia Polytechnic Institute and State University
in 1971, and this funding has been crucially important to my
success in the study of natural products. My initial studies involved
the isolation and structure elucidation of potential anticancer agents
from plants supplied by the National Cancer Institute, and this work
has continued to the present, but with a new focus on the
combination of natural products chemistry and biodiversity con-
servation. The other major thrust of my research has been on the
chemistry and bioactivity of natural products with tubulin-assembly
activity, and this will be discussed ﬁrst.
The Chemistry and Tubulin-Binding Properties of Taxol
Although taxol
1 (1) was ﬁrst isolated by Wall and Wani in the
late 1960s, and its structure published in 1971,
1 it was still very
much a laboratory curiosity to most chemists in 1978. The
oncologists at NCI were not initially enthusiastic about its prospects
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clear activity; it was extremely insoluble in water, and it was dif-
ﬁcult to obtain in quantity from the relatively scarce tree Taxus
breVifolia. In addition to these problems, it had an unknown
mechanism of action. Prospects for its development as an anticancer
drug were thus very slim, but fortunately, some scientists within
NCI, notably Matthew (Matt) Suffness, believed in its prospects
and argued for its further development. These arguments were
buttressed by some encouraging responses for taxol when treating
solid tumor xenografts in nude mice, and in 1977, the NCI
approved funds to develop a formulation of taxol for clinical use
as well as funds to isolate enough taxol for this work. The following
year, Fuchs and Johnson showed that it acted as a spindle poison,
2
and the year after this, in 1979, Susan Horwitz published her pivotal
paper documenting that taxol caused the polymerization of tubulin
to microtubules.
3 This discovery signiﬁcantly increased the at-
tractiveness of taxol as a potential drug and helped to maintain
interest in its development when it encountered problems with
toxicity in its initial clinical trials.
A conversation with my then colleague Bob Holton in 1978
started me on a new and particularly fruitful research area involving
this novel compound. Bob had initiated an approach to the total
synthesis of taxol, but he had no experience with the actual natural
product, and so he suggested a research collaboration. We agreed
that he would continue his total synthetic approach, while I would
investigate the chemistry of taxol, about which very little was then
known. We submitted a joint R01 grant proposal to NIH, but we
were ahead of our time and the proposal was not funded. I thus
began my studies on the chemistry of taxol on a shoestring budget,
although a year or so later I was able to obtain some much needed
support from the American Cancer Society, and later still (once
taxol had become a hot property) I was able to obtain NIH funding
for the work. From the earliest days, I did, however, receive strong
support from Matt Suffness and the Natural Products Branch at
NCI, who provided me with relatively large amounts of crude
taxane mixtures, consisting of side-cuts from the puriﬁcation of
taxol for clinical trials by PolySciences, Inc. These supplies were
crucial to my early work, which could not have been done without
them.
My group’s early studies of the chemistry of taxol have been
reviewed on several occasions
4–6 and will only be summarized
brieﬂy here. Their focus was on the systematic modiﬁcation of
the functional groups of the taxane ring system and on the effect
of variations in the ring system itself on bioactivity. Among
other discoveries, we found that removal of the C1 hydroxyl
group,
7 the C2 benzoyl group,
8 and the C4 acetyl group
9 all
produced analogues with signiﬁcantly reduced bioactivities, but
removal of the C7 hydroxyl group
10 or the C10 acetoxyl group
11
yielded products with much less activity loss. Contraction of
the A-ring gave the A-nortaxol 2, which was several orders of
magnitude less cytotoxic than taxol but which surprisingly
retained much of taxol’s tubulin-polymerization activity.
12
Contraction of the C-ring by an interesting mechanism gave
the C-nortaxol 3, which was signiﬁcantly less active than taxol
both in its cytotoxicity and in its tubulin-assembly activity.
13
The oxetane ring was the focus of several studies. Oxidation at
C7 allowed simple base-promoted opening of the oxetane ring to
give the enone 4,
14 while treatment with Meerwein’s reagent gave
the ring-opened product 5.
12 Both of these compounds were
essentially completely inactive, and these ﬁndings led to the
conclusion that the oxetane ring was essential for activity.
This conclusion was reinforced by the ﬁnding that the
sulfetane analogue 6 was also much less active than taxol.
15
Later work from Dubois et al., however, suggested that the lack
of activity of compounds 4 and 5 was due more to the lack of
the C4-acetate group than of the oxetane ring per se, since the
5(20)-deoxydocetaxel analogue 7 was as active as taxol in
promoting tubulin assembly.
16 The lack of activity of the
sulfetane analogue 6 could then be explained by the fact that
the large size of the sulfur atom prevented proper docking into
the active site on tubulin.
17
One of the most interesting observations to come from this
early work was that changes to the C2-benzoate group had a
profound effect on the activity of taxol. Para-substituents on
the benzene ring uniformly made the resulting taxane much less
active than taxol, but some ortho and meta substituents,
especially the m-azido and m-methoxy substituents, signiﬁcantly
enhanced activity.
18 It was gratifying that this discovery has
been incorporated into two taxanes in preclinical development,
compounds SB-T-11033 (8) and SB-T-121304 (9).
19
The work that my group did, combined with studies from
several other research groups, especially those of Georg,
20
1 The name Taxol has been trademarked by Bristol-Myers Squibb for their
formulation of the chemical compound formerly known as taxol. Because of
the historical nature of this review, the name taxol is retained for compound 1.
No infringement of the Bristol-Myers Squibb trademark is implied.
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21 and Potier,
22 established the main outline of the
structure-activity relationships of taxol. What remained to be
determined was the nature of the crucial interaction between
taxol and tubulin.
The pioneering work of Horwitz
3,23 had shown that taxol
bound stoichiometrically and noncovalently to tubulin, and the
binding site was also shown to be on -tubulin by labeling
studies.
24 Photoafﬁnity labeling studies by Horwitz in collabora-
tion with Swindell showed that 3′ -(p-azidobenzamido)taxol
photolabeled the N-terminal 31 amino acids of -tubulin,
25 while
studies by Horwitz in collaboration with my group showed that
2-(m-azidobenzoyl)taxol photolabeled amino acids 217-231 of
-tubulin.
26 This work did not, however, address the exact
binding site or the conformation of taxol in the binding site.
The complex of taxol with tubulin is polymeric and noncrystal-
line, and so the direct approach of examining the binding site
by X-ray crystallography is not available. Fortunately, the
structure of the tubulin dimer has been determined at 3.7 Å by
electron crystallography of taxol-stabilized zinc-induced tubulin
sheets,
27 and this result established the location of taxol on the
protein. However, this structure lacked the resolution to deﬁne
the detailed conformation of taxol on the tubulin polymer.
Taxol has several ﬂexible side chains, and notably that at
C13, so many possible binding conformations are possible.
Several attempts to deﬁne these conformations have been made
by studies of the solution NMR spectra of taxol. Thus, NMR
studies in nonpolar solvents suggested a “nonpolar” conforma-
tion,
28–30 while a “polar” conformation featuring hydrophobic
interactions between the C2 benzoate, the C3′ phenyl group,
and the C4 acetate was proposed on the basis of NMR studies
in polar solvents.
31–34 A combination of NMR studies using
the NAMFIS deconvolution approach showed that taxol adopts
9-10 conformations in CDCl3,
35 and an analysis of the electron
crystallographic data in combination with the NAMFIS results
suggested that the actual binding conformation had a T-shaped
structure, designated T-taxol (Figure 1).
36
These studies, important as they were, did not provide direct
experimental evidence for the actual conformation of taxol on the
tubulin polymer. This requires a different technique, one that
enables the determination of internuclear distances on the solid
tubulin polymer sample. Fortunately, the relatively new technique
of rotational-echo double-resonance (REDOR) NMR spectros-
copy
37 was developed for precisely this situation, and so we entered
into a fruitful collaboration with Professors Susan Bane (SUNY
Binghamton), Jacob Schaefer (Washington University), and Jim
Snyder (Emory University) to bring the combined forces of
synthetic chemistry, biochemistry, REDOR NMR, and computa-
tional chemistry to bear on the problem of determining the binding
conformation of taxol on -tubulin. A knowledge of this binding
conformation of taxol was an attractive goal because such a
knowledge could guide the design of taxol analogues with improved
activity by locking the molecule into the binding conformation. It
had been suggested that “Taxol’s relatively weak association with
tubulin may, in part, be due to the presence of an ensemble of
nonproductive conformers”,
35 and these studies provided an
opportunity to test this hypothesis. In addition, it was possible that
simpliﬁed taxol analogues could be designed which might retain
all or most of taxol’s anticancer activity.
Our studies began with the synthesis of labeled taxols for
REDOR NMR studies. The ﬁrst compound investigated was the
13C- and ﬂuorine-labeled analogue 10, and this yielded distances
of 10.3 and 9.8 Å for the two distances a and b, respectively.
38 A
later study with the deuterated and ﬂuorinated analogues 11 and
12 gave distances of 6.3, 7.8, and >8 Å for the distances c, d, and
e, respectively.
39 A careful analysis of these data and comparison
with the other proposed conformations indicated that the T-taxol
conformation provided the best ﬁt to the REDOR data (Table 1).
39
Simultaneously with these studies we also designed an
approach to the synthesis of taxol analogues which would
be locked into the T-taxol conformation. Several other
investigators had prepared conformationally locked taxols,
including those based on the nonpolar confomation
40–43 and
on the polar conformation,
44,45 but with one exception
46these
bridged analogues were less bioactive than taxol. An important
conclusion from analysis of the T-taxol structure was that the
C4 acetate group and the C3′ phenyl ring were in close
proximity; the centroid of the C4 acetate was only 2.5 Å from
the ortho position of the C-3′ phenyl ring (Figure 2).
47 This
conclusion informed our synthetic approach, which involved
linking the C4 acetate to the C3′ phenyl ring using linkers of
variable length.
Our retrosynthetic approach was based on using the ﬂexible and
versatile Grubbs’ metathesis reaction as the ﬁnal ring-closing step;
this reaction had previously been successfully used by Ojima in
the synthesis of some bridged taxols.
45 The basic retrosynthetic
FIGURE 1. T-taxol conformation. The C2-benzoate is in the lower
middle and the C13-side chain is to the lower left in this perspective.
TABLE 1. Interatomic Distances for Various Taxol












a 9.6 8.5 9.9 10.3i
b 10.4 6.2 9.1 9.8i
c 5.5 7.2 6.6 6.3h
d 7.4 8.0 7.9 7.8h
e 4.5 12.5 12.2 >8h
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prepared by coupling of the -lactam 15 with the modiﬁed baccatin
III 16. Oleﬁn metathesis of 14 followed by deprotection would
then give the bridged product 13.
Our ﬁrst synthetic products were the compounds 17 and 18,
in which the bridge was linked via the meta position of the
C3′ -phenyl ring. These compounds were both active, but
disappointingly, they were signiﬁcantly less active than taxol
itself. The reason for this relative lack of activity became clear
from a docking study of compound 17 into the taxol binding
pocket of the electron crystallographic structure
48 of -tubulin,
which showed that the meta bridge was interacting with Phe272
of the protein, resulting in the displacement of 17 out of the
binding pocket (Figure 3).
49 This ﬁnding also suggested an
obvious solution, which was to remove the objectionable
interaction by relocating the bridge to the ortho position of the
C3′ -phenyl ring.
Gratifyingly, when this was done, and when the bridge was
adjusted to the correct length, the activity improved dramatically.
The two best derivatives were compounds 19 and 20, with just
two carbons inserted between the C4 acetate methyl group and
the ortho position of the C3′ -phenyl ring.
50 Compound 19, for
example, was 50-fold more potent than taxol to the A2780 ovarian
cancer cell line and was twice as potent toward the PC3 prostate
cancer cell line. It was also almost twice as effective as taxol at
promoting the polymerization of tubulin.
47 Both 19 and 20 were
also much more potent than taxol to taxol-resistant cell lines;
compound 20, for example, was 150-fold more potent than taxol
to the 1A9-PTX10 cell line with the F270V mutation and almost
50-fold more potent than taxol to the 1A9-A8 cell line, with the
T274I mutation.
47 These results thus conﬁrmed the T-taxol
conformation as the bioactive tubulin-binding conformation of
taxol. A combination of NAMFIS analysis of the conformation of
19 with docking into the -tubulin binding site showed that this
compound ﬁt nicely into the taxol binding site and mapped well
onto the T-taxol conformation (Figure 4). Not only was the
objectionable interaction with Phe 272 removed, but a favorable
interaction with a histidine residue was created.
Although these results conﬁrmed the T-taxol conformation
as the tubulin-binding conformation, it was desirable to test the
predictive power of the conformation by carrying out two further
tests, one positive and one negative. As noted earlier, the
A-nortaxol 2 was essentially noncytotoxic, although it retained
moderate tubulin-assembly activity.
12 Could this compound be
made cytotoxic by constraining it to the T-taxol conformation?
The answer was a resounding yes! Compound 21 was prepared
and was found to be approximately one-third as cytotoxic to
PC3 cells as taxol, a far cry from the difference of at least 1000-
fold in cytotoxicity between paclitaxel and compound 2.
Interestingly, the bridged derivative 21 was approximately twice
SCHEME 1
FIGURE 2. T-taxol conformation, illustrating the short H---H distance
between the centroid of the C-4 acetate methyl group and the ortho
position of the C-3′ phenyl ring.
FIGURE 3. T-Taxol (brown) and 17 (blue) bound to -tubulin.
Compound 17 is seated higher in the same pocket as a result of close
contact between the propene moiety of the tether and Phe272 of the
protein (black) at the bottom of the illustration. Modiﬁed from ref 49.
Copyright 2007 American Chemical Society.
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clear testimony to the importance of the T-taxol conformation.
51
The second test was a negative one. Docetaxel (22)i sa
clinically used semisynthetic taxane discovered by Potier and
differs from taxol only in the nature of the N-acyl and C10
substituents;
52 its 10-acetyl derivative 23 is equipotent.
53 If
the carbamate oxygen of docetaxel were linked to the C3-
phenyl group and the C10 hydroxyl group were acetylated,
the resulting compound 24 would possess all the basic
structural features necessary for bioactivity. It would not,
however, be able to adopt the T-taxol conformation (Figure
5) and would thus be expected to be inactive in spite of its
correct chemical connectivity. Compound 24 was prepared
to test this hypothesis,
54 and satisfyingly, it was at least 2
orders of magnitude less active than taxol in the A2780
bioassay and was also signiﬁcantly less active in a tubulin-
assembly assay. This thus provided a conclusive “negative
test” of the T-taxol conformation.
Given that the T-taxol conformation is the most probable
tubulin-binding conformation for taxol, can this knowledge
be used to design simpliﬁed compounds which mimic taxol’s
tubulin-assembly activity? The answer at this point is a
qualiﬁed yes. We synthesized the simpliﬁed analogue 25 and
its diastereomer 26,
55 and both compounds, as well as some
related ones, proved to have clear cytotoxic activity to the
A2780 cell line and also to be effective in promoting the
assembly of tubulin into microtubules. This activity in such
drastically simpliﬁed compounds was encouraging, even
though the cytotoxicities observed were over 2 orders of
magnitude less than that of taxol. A part of the lack of activity
may be due to solubility, since both compounds were very
insoluble in water, but it is probably also due in part to the
fact that the benzoyl group corresponding to the C2 benzoate
of taxol is forced deeper into the hydrophobic binding pocket,
leading to the conclusion that the compounds are not
“sufﬁciently tailored to fully exploit the T-taxol concept.”
55
We are thus continuing our studies in this area in an attempt
to discover simpliﬁed taxols that have superior biological
proﬁles to compounds 25 and 26.
In addition to preparing simpliﬁed taxols, we have sought to
develop improved ways of delivering taxol to the cancer. The most
promising approach has been carried out in collaboration with
colleagues at CytImmune, Inc., and involves the preparation of
taxols with suitable linkers to bond to gold nanoparticles. The
nanoparticles are also loaded with tumor necrosis factor alpha
(TNFR), which targets the taxol-loaded nanoparticles to cancer
cells, where the taxol is released.
56 Initial animal studies of this
construct have been encouraging, and further development is in
progress.
We have also investigated the epothilones. These exciting
anticancer agents have very different structures and origin than
taxol and yet have a very similar mechanism of action.
Epothilones A (27)a n dB( 28) were originally isolated as
antifungal agents from the soil-derived mycobacterium Sor-
angium cellulosum in 1987,
57 but it was the discovery of their
taxol-like tubulin-polymerization activity in 1995
58 and the
elucidation of their absolute conﬁguration in 1996
59 that led to
a surge of interest in their development as potential anticancer
FIGURE 4. T-Conformations of taxol (blue) and 19 (red) in the -tubulin
binding site, the latter having been docked by the Glide software.
Reproduced from ref 47. Copyright 2007 American Chemical Society.
FIGURE 5. Conformation of compound 24, viewed from the same
perspective as T-taxol in Figure 1.
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60–63 Epothilone B (Epo 906, patupilone) is in phase III
clinical trials, and the lactam analogue of epothilone B (ixa-
bepilone, 29) has been approved for clinical use for treatment
of certain forms of breast cancer.
64
Given the success of bridging in improving the activity of
taxol, it was natural to ask whether this strategy could provide
the same beneﬁts to the epothilones. A model for the binding
conformation of epothilone B on tubulin was proposed by
Nettles and Snyder (Figure 6),
65 and this model juxtaposes the
C4-methyl group with the C12-methyl group. We thus elected
to prepare epothilones with bridges linking the C4 and C12
positions.
Extensive synthetic studies, which will be reported elsewhere,
led to the synthesis of the bridged epothilone 31 by oleﬁn
metathesis of the precursor 30. Compound 31 had a much lower
antiproliferative activity toward the A2780 cell line than epothilone
D, and it was also much less active than the deprotected precursor
32. These data suggest either that the original Nettles-Snyder
model does not reveal the correct binding conformation of the
epothilones or that some unusual structural features of compound
31 contribute to its lack of activity. We are thus continuing our
studies in an effort to prepare conformationally constrained
epothilones with improved bioactivity.
Biodiversity Conservation and Drug Discovery in
Madagascar and Suriname
As indicated earlier, my initial studies on natural products were
focused on the discovery of potential anticancer agents from plants,
and this is the second important focus of my group’s work.
Drug discovery from natural sources requires continued access
to plant, marine, and microbial biomass, and as far as plants are
concerned this biomass is concentrated in the tropical rainforests
of the world. These forests cover less than 7% of the earth’s surface,
but hold 50% of its plant biomass. Sadly, tropical forests are
disappearing fast; their coverage is down from 16% of the earth’s
land surface in 1950 to less than 7% today. The preservation of
tropical rainforests and tropical reef systems is or should be an
important part of any comprehensive drug discovery program. One
way to encourage preservation is to demonstrate the value of
tropical forests and reef systems as potential sources of new
pharmaceutical or agrochemical products. The Rio Convention on
Biological Diversity (CBD) in 1992 established three main goals:
the conservation of biological diversity, the sustainable use of its
components, and the fair and equitable sharing of the beneﬁts from
the use of genetic resources. These objectives were subsequently
incorporated into the innovative International Cooperative Biodi-
versity Group (ICBG) program based at the Fogarty International
Institute at NIH, and we were fortunate to receive an award under
this program to carry out drug discovery and biodiversity conserva-
tion work in Suriname and later in Madagascar. Some recent
chemical and conservation results from this work will be described
below. These results are all from my laboratory and do not include
other discoveries made by our ICBG partners Eisai Research
Institute and Dow AgroSciences.
The ipomoeassins are a series of related resin glycosides
isolated from the Suriname plant Ipomoea squamosa. Their
isolation was challenging, but eventually 60 mg of the most
abundant compound (ipomoeassin A, 33) was obtained, and
its structure was elucidated by NMR and mass spectra
combined with chemical conversions and Mosher ester
formation for determination of stereochemistry. The com-
pounds were of interest in part because of their unusual
structures but primarily because they showed potent but
selective antiproliferative activity to the A2780 cell line.
66
Ipomoeassin A showed selective antiproliferative activity in
the NCI 60-cell line screen, and its pattern of activity did
not match other known anticancer agents when subjected to
a COMPARE analysis. These compounds have been synthe-
sized
67 and are currently being considered for development
by the National Cancer Institute.
The schweinfurthins are a class of highly potent cytotoxic
agents that were originally discovered by Beutler.
68 We
isolated four new compounds, of which schweinfurthins E
(34)a n dG( 35) had submicromolar antiproliferative activity
against the A2780 ovarian cancer cell line.
69 These com-
pounds are being evaluated by a pharmaceutical partner
against additional cell lines, with a view to discerning their
development potential. Schweinfurthin F has recently been
synthesized by Wiemer,
70 and the relative simplicity of these
compounds makes them attractive candidates for synthetic
chemistry and SAR studies should their biology warrant it.
The three particularly complex cytotoxic triterpenoid saponins
36-38 were obtained from Albizia gummifera; their structure
FIGURE 6. (a) Nettles-Snyder proposed epoA model based on EC
density (left) with juxtaposition of the C4-methyl and C12-H (methyl
for epoB); r(C---C) ) 4.5 Å. (b) MMFF-energy minimized structures
of the EC template and the designed bridged epoD analogue 31
(overlayed with three-point selection in PyMol).
3980 J. Org. Chem. Vol. 73, No. 11, 2008elucidation required a demanding interpretation of complex
NMR spectra.
71 Although these compounds had micromolar
antiproliferative activity against the A2780 ovarian cancer cell
line, they are unlikely to be attractive development candidates
because of their complex structures and presumed unfavorable
pharmacokinetics.
A Madagascar plant of the Malleastrum genus yielded several
new bioactive diterpenoids, of which 39 is one example,
72 while
Casearia nigrescens yielded several new diterpenoids with sub-
micromolar activities, including compound 40.
73 Finally, the new
and relatively unusual cardenolide 41 from an Elaeodendron sp.
had potent antiproliferative activity to the A2780 cell line.
74
In addition to the chemical work, the Suriname and Mada-
gascar ICBG programs have made signiﬁcant contributions to
conservation and economic development in their respective
countries. In Suriname, the ICBG Program contributed to the
establishment of the Central Suriname Nature Reserve, a
UNESCO World Heritage Site.
75 This important conservation
success was brought about primarily through a cooperative
agreement between Conservation International, a partner in the
Suriname ICBG program, and the Government of Suriname,
but the ICBG program provided important scientiﬁc justiﬁcation
for the value of the rain forest and thus of establishing this
protected area.
In Madagascar, the Montagne des Franc ¸ais is an area of
outstanding natural beauty and importance in the north of the
country. The work to achieve protected area status for this area
was complex and included making a botanical and economic
evaluation, developing a plan for an ecotourism concession,
establishment of steering committees to lead the process of
setting up the new protected area, development of a community
structure to assist with security and conﬂict management,
consultation with local and regional authorities, development
of the legal tools needed for protected status, and compilation
of a complete initiative dossier documenting these and other
steps for submission to the necessary government departments.
As a result of all these steps, the Montagne des Franc ¸ais was
granted temporary protected status in the Syste `me d’Aires
Prote ´ge ´es de Madagascar (SAPM) in 2006 and will achieve full
protected status in mid-2008. These and other conservation
achievements were accomplished by the ICBG Madagascar
partners Centre National d’Application des Recherches Phar-
maceutiques, Conservation International, and the Missouri
Botanical Garden. These and other conservation and develop-
ment successes have given signiﬁcant added value to the
Suriname and Madagascar ICBG programs, over and above the
value of the novel bioactive natural products isolated.
Perspective
The foregoing account gives some taste of the joys and the
challenges of natural products research in the 21st century.
Natural products have proven to be the most reliable single
source of new and effective drugs, and especially anticancer
agents. Thus, Newman and Cragg have shown that 63% of
anticancer drugs introduced over the last 25 years are natural
products or can be traced back to a natural products source.
76
Natural products have not only yielded new and effective drugs,
but they have also provided insight into new mechanisms of
action, and cancer treatment would be immeasurably poorer
without the insights and the compounds provided from Nature.
It is thus instructive to ask why it is that natural products have
proved to be such a proliﬁc source of bioactive agents. There
are several reasons, but certainly one of the most important is
that plants and other organisms produce many biologically active
substances for defense and other purposes, and so these
substances are uniquely tailored to ﬁt into a biological receptor
of some kind.
77 Second, natural products are often large
molecules with built-in chirality and are thus uniquely suited
to bind to complex proteins and other biological receptors. As
a result of these considerations, there is a high correlation
between the properties of drugs and those of natural products.
78,79
The misconception that natural products research has not
produced many drugs recently is laid to rest by Butler, who
writes “Another misconception has been that NP research has
failed to deliver many new compounds that have undergone
clinical evaluation over the last few years. However, in reality,
15 NP-derived drugs have been launched in the key markets of
the United States, Europe, and Japan over the last three years,
and an additional 15 NP-derived compounds were in Phase III
clinical trials at the end of 2003.”
80
Although it has been enormously successful, the pharma-
ceutical industry is under continuing pressure to speed up
the process of drug discovery, and the natural products
approach to drug discovery must compete in the scientiﬁc
marketplace with other approaches which might appear to
give more rapid short-term results. It is thus essential that
natural products research become as efﬁcient as possible. The
three major components of any successful natural products
drug discovery program are the availability of adequate
source materials, the use of new and selective bioassays, and
the use of rapid and efﬁcient isolation and structure elucida-
tion methods. The available source materials include not only
the traditional microbial, plant, and marine organisms but
also novel source materials such as extremophiles and
“unculturable” microorganisms. The use of novel culturing
environments or of heterologous DNA-based approaches, for
example, has given encouraging results in the search for new
antibiotics.
81 It goes without saying that any approach that
involves collection of biomass must be done in a way that is
fully consistent with the CBD and with full recognition of
the rights of the host country. The second key component of
a successful natural products based drug discovery program
is the use of selective and predictive bioassays. In the
anticancer area, these will include assays for individual
enzymes such as the protein kinases and phosphatases
82–84
rather than whole cell cytotoxicity assays, while in the
antiinfective area a genetics-based ﬁtness test holds promise
for detecting novel agents with known and unusual mecha-
nisms of action.
85 The third key requirement is that isolation
and structure elucidation be carried out as efﬁciently as
possible. This will usually require some level of dereplication
to avoid the reisolation of known compounds, as well as the
use of the best NMR and mass spectrometric instrumentation
available today.
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supply, which can be severe in the case of plant and especially
marine natural products, and of analogue synthesis. Although
compound supply will always be a factor in evaluating
potential drug candidates, it need not be a fatal one. The
problem has been met in several ways in the past. In the
case of taxol, a partial synthesis from 10-deacetylbaccatin
III proved crucial in the early years,
86 while it is currently
produced by plant tissue culture
87 as well as by direct
isolation and semisynthesis. Another example is the marine
natural product ecteinascidin (Yondelis), which is prepared
by semisynthesis from the microbial natural product cyanosa-
fracin.
88 In other cases, direct synthesis is possible; the most
dramatic example of this is the approximately 70-step
synthesis used for production of the phase III clinical
candidate eribulin, a simpliﬁed derivative of the complex
marine natural product halichondrin B.
89 It is thus safe to
say that the combination of synthetic ingenuity with informed
sourcing will succeed in providing adequate supplies of most
if not all natural products of pharmaceutical interest.
The second consideration is that chemical synthesis can often
produce modiﬁed natural products with improved properties.
Natural products can thus also lead to new analogues with
greater synthetic accessibility or improved activity, as exempli-
ﬁed by the many analogues of taxol that are in clinical trials
90
as well as numerous other examples such as the exciting activity
of 26-triﬂuoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as
an improved epothilone analogue.
91
In summary, the future of natural products research remains
bright. If novel source organisms are combined with innovative
bioassays and efﬁcient structure elucidation, the natural products
approach to drug discovery will continue to compete very
effectively with other approaches, and will continue to contribute
many novel bioactive agents for pharmaceutical use, as well as
providing synthetic chemists with challenging targets for
synthesis and for improvement.
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